6533b828fe1ef96bd12890f0

RESEARCH PRODUCT

Use of rivaroxaban for the prevention of stroke in patients with nonvalvular atrial fibrillation in Spain

Irene Pastor-galánEdelmira MartíPaula AmatCarlos SolanoAlejandra SegadoMaría José RemigiaBlanca Navarro

subject

Malemedicine.medical_specialtyHemorrhage030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRivaroxabanRisk FactorsInternal medicineAtrial FibrillationmedicineHumansIn patient030212 general & internal medicinePractice Patterns Physicians'StrokeAgedRetrospective StudiesAged 80 and overRivaroxabanbusiness.industryRetrospective cohort studyMean ageAtrial fibrillationmedicine.diseaseStrokeSpainCohortMolecular MedicineFemaleCardiology and Cardiovascular MedicinebusinessMajor bleedingFactor Xa Inhibitorsmedicine.drug

description

Aim: To analyze the clinical profile and rates of stroke, major bleeding and intracranial hemorrhage of patients with atrial fibrillation (AF) treated with rivaroxaban in clinical practice. Methods: Retrospective study of AF patients anticoagulated with rivaroxaban in a Healthcare Area of Valencia, Spain. Patients started treatment with rivaroxaban from July 2012 to December 2015. Results: A total of 230 patients (mean age 76.9 ± 9.9 years; CHA2DS2-VASc 4.3 ± 1.7; HAS-BLED 1.7 ± 0.9) were included. Rates of stroke, major bleeding and intracranial bleeding were 0.4, 1.9 and 0.5 events per 100 patient-years, respectively. Conclusion: In this cohort of AF patients anticoagulated with rivaroxaban, despite patients being older and having a high thromboembolic risk, rates of stroke, major bleeding and intracranial bleeding were low.

yearjournalcountryeditionlanguage
2018-06-01Future Cardiology
https://doi.org/10.2217/fca-2018-0020